Katherine Stueland Sells 1,653 Shares of GeneDx (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 1,653 shares of the firm’s stock in a transaction dated Thursday, January 29th. The stock was sold at an average price of $94.00, for a total value of $155,382.00. Following the transaction, the chief executive officer owned 16,458 shares in the company, valued at approximately $1,547,052. This trade represents a 9.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Katherine Stueland also recently made the following trade(s):

• On Tuesday, December 16th, Katherine Stueland sold 10,857 shares of GeneDx stock. The shares were sold at an average price of $143.89, for a total value of $1,562,213.73.
• On Tuesday, December 9th, Katherine Stueland sold 3,639 shares of GeneDx stock. The stock was sold at an average price of $159.28, for a total transaction of $579,619.92.

GeneDx Stock Down 3.8%

Shares of NASDAQ WGS opened at $95.23 on Wednesday. GeneDx Holdings Corp. has a 52-week low of $55.17 and a 52-week high of $170.87. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.59 and a current ratio of 2.71. The stock has a market cap of $2.75 billion, a P/E ratio of 1,058.11 and a beta of 2.00. The firm has a 50 day moving average price of $131.03 and a 200 day moving average price of $125.13.

Institutional Trading of GeneDx

A number of institutional investors have recently made changes to their positions in WGS. Royal Bank of Canada boosted its holdings in GeneDx by 30.2% during the first quarter. Royal Bank of Canada now owns 29,479 shares of the company’s stock worth $2,611,000 after purchasing an additional 6,840 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of GeneDx by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock worth $677,000 after buying an additional 453 shares during the last quarter. NewEdge Advisors LLC grew its holdings in shares of GeneDx by 270,700.0% in the 1st quarter. NewEdge Advisors LLC now owns 2,708 shares of the company’s stock valued at $240,000 after acquiring an additional 2,707 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of GeneDx by 67.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company’s stock valued at $2,500,000 after acquiring an additional 11,375 shares during the last quarter. Finally, Chung Wu Investment Group LLC raised its holdings in GeneDx by 8.2% during the second quarter. Chung Wu Investment Group LLC now owns 3,300 shares of the company’s stock worth $305,000 after acquiring an additional 250 shares in the last quarter. Institutional investors own 61.72% of the company’s stock.

Key Headlines Impacting GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Analyst consensus remains favorable — the stock carries a “Moderate Buy” consensus and several firms have recently reaffirmed or raised price targets, which supports longer-term upside. Analyst Consensus
• Neutral Sentiment: Institutional ownership is sizable (~61.7%) with modest quarter-to-quarter adjustments by some funds; that large institutional base can dampen short-term volatility but also concentrates moves when sentiment shifts. Institutional & Insider Summary
• Neutral Sentiment: Reported short-interest data in the recent update is effectively zero/insignificant (likely a data anomaly), so short-covering dynamics are not a clear driver of today’s move. No clear short squeeze risk is indicated.
• Negative Sentiment: Multiple insider sales by senior executives: COO Bryan Dechairo sold 3,413 shares (~$339.7k) and CEO Katherine Stueland sold 1,653 shares (both late January transactions disclosed in SEC filings). Such clustered insider selling by C‑suite members can signal to the market a reduced near-term insider conviction. COO Form 4 CEO Form 4
• Negative Sentiment: CFO Kevin Feeley also sold shares (317 shares reported), adding to the pattern of insider sales and amplifying investor concern about executive liquidity events. CFO Sale
• Negative Sentiment: Technical picture is unfavorable: the share price sits well below the 50-day and 200-day moving averages cited in recent summaries, which can prompt momentum selling from traders using technical triggers. Price & Technicals

Wall Street Analysts Forecast Growth

WGS has been the topic of several recent analyst reports. BTIG Research lifted their target price on GeneDx from $165.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Wall Street Zen upgraded GeneDx from a “hold” rating to a “buy” rating in a report on Saturday. Guggenheim reissued a “buy” rating and set a $170.00 target price (up from $115.00) on shares of GeneDx in a research note on Wednesday, October 29th. Weiss Ratings restated a “sell (d)” rating on shares of GeneDx in a report on Wednesday, January 21st. Finally, Canaccord Genuity Group lifted their price target on shares of GeneDx from $160.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, December 22nd. Six equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $138.13.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.